When it comes to investing in biotech stocks, the author of today’s article points out that “By identifying companies that are likely to report rapid revenue growth in the next few years, you’ll be most of the way toward profit.” Of course, identifying those companies is no easy task, but he proceeds to highlight one likely candidate that is “putting the finishing touches on a few of its longest-incubating projects and awaiting the final go-ahead from regulators. If all goes well, it’ll soon be a self-sustaining competitor in the diabetes space.” For more, CLICK HERE.
On The Cusp Of Commercializing Its First Drug, Now May Be The Time To Buy This Biotech Stock
- by Alex Clarke
